Boardroom Alpha
Boardroom Alpha
CHGG · Current Report (Form 8-K) · Filed June 17, 2026

Chegg Inc — Current Report (Form 8-K)

Form
8-K
Filed
June 17, 2026
Period
Jun 12, 2026
Ticker
CHGG
Accession
0001364954-26-000066
Boardroom Alpha · Filing insights

Chegg stockholders elected directors and approved all four proposals, including a board-discretion reverse stock split.

About Chegg Inc
Market cap
$88M
1Y TSR
−28.3%
3Y TSR
−55.5%
Board grade
C-
Sector
Consumer Defensive
CEO
Daniel Rosensweig
Last annual meeting: Jun 12, 2026 · View full Chegg Inc profile →
chgg-20260612

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): June 12, 2026
Chegg, Inc.
(Exact name of registrant as specified in its charter)
Delaware001-3618020-3237489
(State or other jurisdiction of incorporation)(Commission File Number) (IRS Employer Identification No.)

2261 Market Street STE 46218
San Francisco,California 94114
(Address of principal executive offices) (Zip Code)
(408) 855-5700
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, $0.001 par value per shareCHGGThe New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.






Item 5.07    Submissions of Matters to a Vote of Security Holders.

On June 12, 2026, Chegg, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Meeting”). At the Meeting, the stockholders voted on the following four proposals, each of which is described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 28, 2026.

The nominated directors were elected and the other proposals were approved by the required stockholder vote. The final voting results with respect to each proposal are set forth in the following tables.

1.To elect two Class I directors to serve until the third annual meeting of stockholders following this Meeting, and one Class III director to serve until the second annual meeting of stockholders following this Meeting, each to hold office until their successor is duly elected and qualified or until their resignation or removal:

NomineeForAgainstAbstainBroker Non-Votes
Dan Rosensweig (Class I)34,892,58410,617,10389,65739,580,243
Ted Schlein (Class I)34,137,19311,364,24897,90239,580,244
Renee Budig (Class III)35,433,38810,076,08789,87039,580,242

2.To approve, on a non-binding advisory basis, the compensation of our named executive officers for the year ended December 31, 2025:

ForAgainstAbstainBroker Non-Votes
34,129,51411,226,027243,80339,580,243

3.To ratify the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026:

ForAgainstAbstainBroker Non-Votes
80,912,9974,153,126113,463

4.To approve an amendment to our Restated Certificate of Incorporation to effect a reverse stock split of our outstanding common stock at a ratio ranging from between 1-for-4 and 1-for-15 (the “Reverse Stock Split”), with the determination of whether to effect the Reverse Stock Split and the ratio to be used for any Reverse Stock Split to be approved by the Board in its sole discretion:

ForAgainstAbstainBroker Non-Votes
77,625,7477,324,294229,544



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
CHEGG, INC.
By: /S/ DAVID LONGO
David Longo
Chief Financial Officer and Corporate Secretary
Date: June 17, 2026

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Chegg Inc (CHGG)

Reference

Frequently asked questions

When did Chegg Inc file this 8-K?
Chegg Inc (CHGG) filed this Current Report (Form 8-K) with the SEC on June 17, 2026. The accession number assigned by EDGAR is 0001364954-26-000066.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Chegg stockholders elected directors and approved all four proposals, including a board-discretion reverse stock split. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Chegg Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Chegg Inc has filed under CIK 1364954, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer